Between the Biotech Waves

Nessan Bermingham PhD
  • 4,9 (21)
  • БИОНАУКИ
  • КАЖДЫЕ ДВЕ НЕДЕЛИ
Between the Biotech Waves

Between the Biotech Waves—discussing recent developments and market dynamics impacting the biotech sector.

  1. 02.07.2024

    Episode 35: A Between the Biotech Waves Conversation with Mike Curtis, President & CEO of eGenesis

    Welcome back to Between the Biotech Waves. I am sorry for the lack of episodes over the past few months, unfortunately life threw me a curve ball that I have been taking care of but now back and ready to go!Today it gives me great pleasure to introduce Mike Curtis, President and CEO of eGenesis. You may recall seeing eGenesis on the front cover of the New York Times recently following the first successful xenotransplantation of a genetically modified porcine kidney. This followed years of wor...

    1 ч. 5 мин.

  2. 19.07.2023

    Episode 33: A Between the Biotech Waves conversation with Eliot Forster, xCEO of F-star Therapeutics

    Today I am talking to Eliot Forster xCEO of F-star Therapeutics.Eliot was at helm of the company as they reversed merged into Springbank Pharmaceuticals & through the recently announced acquisition by Sino Biopharma, a transaction that generated a lot of interest given the very public interactions with CFIUS.Prior to F-star, Eliot was CEO of Immunocore, Creabilis and Solace Pharmaceuticals following his multiple roles at Pfizer which included head of development and operations, European U...

    1 ч. 5 мин.

  3. 19.07.2023

    Episode 32: The Triplet Therapeutics story, from concept to birth, life & death.

    Today we have an unusual (& long) podcast where we talk to key members of the Triplet Therapeutics management team. Triplet was founded to develop antisense oligonucleotides targeting the DNA damage response pathway that has been implicated in driving repeat disorders including Huntington's disease - the lead indication for Triplet. The team discusses the challenges in building the company and what ultimately led to it's demise.

    1 ч. 46 мин.

  4. 02.07.2023

    Episode 31: A Between the Biotech Waves Conversation with Tim Yu

    Today we are talking to Tim Yu. Tim is attending physician at the division of genetics and genomics at Boston Children’s Hospital and assoc prof of Pediatrics at Harvard Medical School. The scope of work that Tim does is well beyond what can be covered in this intro however I have gotten to know Tim through his leading the emerging filed of N of 1 plus drugs. Tim worked with Julia Vitarello to develop Milasen leading the way in truly personalized therapeutics. Please join me in welcoming Tim...

    56 мин.

  5. 02.07.2023

    Episode 30: A Between the Biotech Waves conversation with Barry Greene, CEO of Sage Therapeutics

    Today we are talking to Barry Greene, CEO of Sage Therapeutics. Barry has had an amazing career spanning over 30 years in the biotech industry. Prior to Sage Barry was President of Alnylam shepherding it with John through its evolution from basic science through commercial product launch. Prior to ALNY Barry was general manager of Oncology at Millennium where he was directly involved in the approval and launch of Velcade. He is currently a member of the board of the Pharmaceutical Research an...

    46 мин.

  6. 16.06.2023

    Episode 29: A Between the Biotech Waves conversation with Joel Marcus, Founder & Exec Chair of Alexandria Real Estate

    Today we are talking to Joel Marcus. He has shaped the life sciences industry through ARE from the buildings we use to venture and fund investing. His impact can be directly seen in major cities across the US from Boston to NY to San Francisco with over 22million sq ft of space. Beyond Alexandria he is a philanthropist who supports veterans and their families, and through his initiatives people suffering from the opioid crisis, homelessness and mental illness. Please join me in welcoming Joel.

    53 мин.

  7. 16.06.2023

    Episode 28 A Between the Biotech Waves Conversation with Rachel Meyers

    Today we are talking to Rachel Meyers. Rachel was most recently the CSO of Faze Medicines a company she launched with TRV to focus on the regulation of biomolecular condensates to treat disease. Prior to Faze she was an EIR at TRV prior to which she spent nearly 2 decades at Alnylam. I have had the pleasure of working with Rachel getting an appreciation not only of her as a scientist, entrepreneur and operator but also her pure love of science, focus on company culture and her passion for div...

    58 мин.

  8. 26.04.2023

    Episode 27 A Between the Biotech Waves Conversation with Aoife Brennan, CEO of Synlogic

    Today we are talking to Aofie Brennan, president and CEO of Synlogic. Aoife was trained as a doctor at Trinity College Dublin following which she moved to the US. After completing her postdoctoral research at Beth Israel Aofie joined TolerX focused on developing autoimmune therapies for type I diabetes. Following which Aoife spent 6 years at Biogen ultimately becoming head of Rare Disease Innovation, she was involved in the development of Spinraza, Alprolix and Eloctate. Aoife moved from Biog...

    1 ч. 7 мин.
См. все (34)

Оценки и отзывы

4,9
из 5
Оценок: 21

Об этом подкасте

Between the Biotech Waves—discussing recent developments and market dynamics impacting the biotech sector.

Информация

  • Автор
    Nessan Bermingham PhD
  • Годы выхода
    2022 - 2024
  • Выпуски
    34
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © 2024 Between the Biotech Waves
  • Сайт подкаста
    Between the Biotech Waves

Вам может также понравиться

Чтобы прослушивать выпуски с ненормативным контентом, войдите в систему.

Следите за новостями подкаста

Войдите в систему или зарегистрируйтесь, чтобы следить за подкастами, сохранять выпуски и получать последние обновления.
Выберите страну или регион

Африка, Ближний Восток и Индия

Азиатско-Тихоокеанский регион

Европа

Латинская Америка и страны Карибского бассейна

США и Канада